oncology

Showing 15 posts of 328 posts found.

adaptimmune_lab_scientists_growing_research_cells_jpg-web

Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial

August 4, 2016
Research and Development Adaptimmune, T cell, oncology, t-cell

Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a partial clinical hold has been …

celgene_1_02

Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma

July 15, 2016
Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology

Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma. 

lab

Federal panel to review proposal for first human CRISPR test

June 20, 2016
Research and Development, Sales and Marketing crispr, gene editing, human testing, oncology

A US Federal safety board is set to review a proposal for the first human use of the gene editing …

Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer

June 17, 2016
Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …

ascologo

Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study

June 7, 2016
Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social

Cancer drugs are less affordable in low-income countries, despite the lower retail prices, according to a study released at the …

cancer_cells

Global oncology market to reach $150 billion by 2020, says IMS Health

June 2, 2016
Research and Development IMS Health, annual global growth, cancer drugs, oncology

Global sales of oncology drugs rose to $107 billion in 2015, according to a new IMS Health report, with growth …

Jazz Pharmaceuticals to acquire Celator in $1.5 billion deal

May 31, 2016
Manufacturing and Production, Sales and Marketing $1.5 billion, Vyxeos, acquisition, celator, jazz, leukaemia, merger, oncology

Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that it has entered into a definitive merger agreement with Celator Pharmaceuticals (NASDAQ: CPXX) …

needles

BTG acquires promising oncology pipeline in Galil Medical takeover

May 9, 2016
Manufacturing and Production, Research and Development, Sales and Marketing $84 million, BTG, cryoablation, galil medical, oncology, takeover

BTG (LSE: BTG) has announced that is has agreed to acquire Galil Medical, a leading provider of cryoablation products for …

tug-of-war

Focus: Medivation tug-of-war rumbles on

May 6, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war

Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …

2174264_eisai_logo-web

Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe

May 5, 2016
Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma

The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …

headquarters_3_web

Eli Lilly’s cancer drug candidate scores FDA priority review

May 5, 2016
Eli Lilly, US FDA, oncology, regulation

US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …

sample

Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …

bms_building_uk

Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer

April 19, 2016
Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo

New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …

opdivo_1

Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials

April 19, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous

Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …

The Gateway to Local Adoption Series

Latest content